This invention relates to novel complexes that can be used to target tumor cells. The complexes include a ligand that can bind metal ions including radioactive lanthanide ions. The complexes can mimic α
ν
β3 integrin receptor antagonists and deliver the complexed radioactive metals to the tumor cells.